{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=allogeneic+hematopoietic+cell+transplantation&page=31", "query": { "intervention": "allogeneic hematopoietic cell transplantation", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 2002, "total_pages": 201, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=allogeneic+hematopoietic+cell+transplantation&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=allogeneic+hematopoietic+cell+transplantation&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T18:23:27.957Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06938867", "title": "Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "E Coli Infections", "Allogenic Transplant Patients" ], "interventions": [ { "name": "SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli", "type": "BIOLOGICAL" }, { "name": "Placebo 10 mL", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SNIPR Biome Aps.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2024-12-04", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 10, "location_summary": "Duarte, California • San Francisco, California • Baltimore, Maryland + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06938867" }, { "nct_id": "NCT04984356", "title": "A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "WU-CART-007", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Allotera Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 28, "start_date": "2022-01-14", "completion_date": "2024-08-08", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 7, "location_summary": "Duarte, California • Los Angeles, California • Tampa, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04984356" }, { "nct_id": "NCT01134081", "title": "Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gingival Recession" ], "interventions": [ { "name": "CelTx™", "type": "BIOLOGICAL" }, { "name": "Free Gingival Graft", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2008-01", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2017-08-21", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01134081" }, { "nct_id": "NCT03394365", "title": "A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)", "Solid Organ Transplant Complications", "Lymphoproliferative Disorders", "Allogeneic Hematopoietic Cell Transplant", "Stem Cell Transplant Complications" ], "interventions": [ { "name": "tabelecleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 115, "start_date": "2017-12-29", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 40, "location_summary": "Duarte, California • La Jolla, California • Loma Linda, California + 28 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03394365" }, { "nct_id": "NCT02061800", "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia (CML)", "Acute Myelogenous Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Juvenile Myelomonocytic Leukemia (JMML)", "Acute Lymphoblastic Leukemia (ALL)", "Lymphoma (Hodgkin's and Non-Hodgkin's)" ], "interventions": [ { "name": "CliniMACS CD34+ Reagent System", "type": "DEVICE" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Diane George", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 14, "start_date": "2013-06-03", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061800" }, { "nct_id": "NCT07800871", "title": "FT839 in Autoimmune Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ANCA-Associated Vasculitis (AAV)", "Idiopathic Inflammatory Myositis (IIM)", "Rheumatoid Arthritis (RA)", "Systemic Lupus Erythematosus (SLE)", "Systemic Sclerosis (SSc)" ], "interventions": [ { "name": "FT839", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 446, "start_date": "2026-10", "completion_date": "2040-10", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 1, "location_summary": "Fullerton, California", "locations": [ { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07800871" }, { "nct_id": "NCT02934477", "title": "Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Hematopoietic Stem Cell Transplant", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 650, "start_date": "2016-11", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2023-08-30", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02934477" }, { "nct_id": "NCT00003145", "title": "Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase of Disease", "Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase of Disease", "Recurrent Disease" ], "interventions": [ { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Therapeutic Allogeneic Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "74 Years", "sex": "ALL", "summary": "Up to 74 Years" }, "enrollment_count": 18, "start_date": "1997-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-01-10", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 6, "location_summary": "Duarte, California • Stanford, California • Denver, Colorado + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Dallas", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003145" }, { "nct_id": "NCT03878199", "title": "Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Essential Thrombocythemia", "Myelofibrosis", "Myeloproliferative Neoplasm", "Polycythemia Vera", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-02-20", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 3, "location_summary": "Columbus, Ohio • Portland, Oregon • Dallas, Texas", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878199" }, { "nct_id": "NCT03354728", "title": "Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cytomegaloviral Infection", "Hematopoietic Cell Transplant Recipient" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 80, "start_date": "2018-05-11", "completion_date": "2026-12-11", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-15T18:23:27.957Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03354728" } ] }